This company has been marked as potentially delisted and may not be actively trading. NASDAQ:PRTO Proteon Therapeutics (PRTO) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisCompetitorsTrendsBuy This Stock About Proteon Therapeutics Stock (NASDAQ:PRTO) Get Proteon Therapeutics alerts:Sign Up Key Stats Today's Range$3.02▼$3.1250-Day Range$0.84▼$25.1352-Week Range$0.22▼$3.94Volume103,503 shsAverage Volume1.11 million shsMarket Capitalization$67.20 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Proteon Therapeutics, Inc., a late-stage biopharmaceutical company, focuses on the development of pharmaceuticals to address the needs of patients with renal and vascular disease. Its lead product candidate is vonapanitase, an investigational drug intended to enhance hemodialysis vascular access outcomes. The company develops vonapanitase, a recombinant human elastase, which has completed Phase II and Phase III clinical trials for patients with chronic kidney disease. It is also evaluating vonapanitase in a Phase I clinical trial in patients with peripheral artery disease. The company was founded in 2001 and is based in Waltham, Massachusetts. Read More Receive PRTO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Proteon Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. PRTO Stock News HeadlinesProQR Therapeutics price target raised to $4 from $2.50 at ChardanNovember 9, 2024 | markets.businessinsider.comProtara Therapeutics (TARA) Earnings Dates & ReportsNovember 1, 2024 | investing.comREVEALED: Something Big Happening Behind White House Doorswhat I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for yourself. Once you see what’s unfolding behind the scenes, you’ll understand why I rushed this interview and opportunity to you today.September 18 at 2:00 AM | Paradigm Press (Ad)ProQR Therapeutics upgraded to Strong Buy from Outperform at Raymond JamesOctober 29, 2024 | markets.businessinsider.comPROCEPT BioRobotics Posts Strong Q3 Earnings, Joins Monte Rosa Therapeutics, EyePoint Pharmaceuticals And Other Big Stocks Moving Higher On MondayOctober 28, 2024 | msn.comProQR Announces Major Share Offering AgreementOctober 25, 2024 | markets.businessinsider.comSeaport raises $225m to advance portfolio of neuropsychiatric prodrugsOctober 22, 2024 | msn.comProdrugs and patents: Enhancing therapy adherence and reducing side effectsSeptember 11, 2024 | msn.comSee More Headlines PRTO Stock Analysis - Frequently Asked Questions How were Proteon Therapeutics' earnings last quarter? Proteon Therapeutics Inc (NASDAQ:PRTO) announced its quarterly earnings data on Thursday, October, 31st. The biopharmaceutical company reported ($0.08) EPS for the quarter, beating the consensus estimate of ($0.09) by $0.01. What other stocks do shareholders of Proteon Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Proteon Therapeutics investors own include Bristol Myers Squibb (BMY), SCYNEXIS (SCYX), Agile Therapeutics (AGRX), ImmunoGen (IMGN), Onconova Therapeutics (ONTX), Sierra Oncology (SRRA) and Tonix Pharmaceuticals (TNXP). Company Calendar Last Earnings10/31/2019Today9/18/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological Products, Except Diagnostic Sub-IndustryN/A Current SymbolNASDAQ:PRTO CIK1359931 Webwww.proteontherapeutics.com Phone781-890-0102FaxN/AEmployees17Year FoundedN/AProfitability EPS (Trailing Twelve Months)($1.15) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$20.73 million Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on Assets-118.68% Debt Debt-to-Equity RatioN/A Current Ratio5.98 Quick Ratio5.98 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value($0.06) per share Price / Book-50.50Miscellaneous Outstanding Shares22,179,000Free FloatN/AMarket Cap$67.20 million OptionableNot Optionable Beta0.60 Elon Musk's Next MoveExplore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.Get This Free Report This page (NASDAQ:PRTO) was last updated on 9/18/2025 by MarketBeat.com Staff From Our PartnersWarren Buffett’s #1 AI Stock: Not Mag 7, And NOT on the NasdaqNew Amazon Crisis Could Tank U.S. Stock Market A new panic is halting AI projects at Amazon and could split...Altimetry | SponsoredREVEALED: Something Big Happening Behind White House Doorswhat I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredWhat a Former CIA Agent Knows About the Coming Collapse This isn’t just another gold investing book—it’s a survival playbook written by a former CIA officer trained...Advantage Gold | SponsoredCrypto Gets Official Government Backing—Here's the WinnerTrump Just Signed the GENIUS Act—One Coin is About to Explode We're at the BEGINNING of smart money really ...Crypto 101 Media | SponsoredTrump’s Plan May Undo 1933’s Biggest Financial InjusticeTrump's Reset Can Give Birth To America's Greatest Era Yet A 90-Year cycle may end soon, creating real weal...American Hartford Gold | SponsoredNVIDIA's Worst Nightmare?$2 TRILLION Quantum Gold Rush While everyone fights over expensive AI stocks... McKinsey just revealed the ...The Oxford Club | Sponsored$100 Trillion “AI Metal” Found in American Ghost TownJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Proteon Therapeutics Inc Please log in to your account or sign up in order to add this asset to your watchlist. Share Proteon Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
